RxDoctor Payments Data

Stuart Fox, MD

Gynecology · Racine, WINPI 1366472235

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (49.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Axonics, Inc. accounts for 74.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $2,415 and has fallen 99.0% since, to $25 in 2025.

$4,946in general payments, 2019–2025

Across 64 payments — averaging $77.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$4K
  • Astellas Pharma US Inc$765
  • AbbVie$308
  • EMD Serono, Inc.$82
  • Medtronic$65
  • Boston Scientific$25
  • plus $25 from 2 others

What the payments were for

  • Travel & lodging$2,43649%
  • Food & beverage$2,02641%
  • Education$48510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecology providers in Wisconsinto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$116,154
Medicare patients
175
Services billed
5,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron519$342,689
PremarinEstrogens, Conjugated103$46,660
Estradiol236$15,037
ElmironPentosan Polysulfate Sodium12$8,923
FemringEstradiol Acetate12$8,304
Mirabegron ErMirabegron12$6,570
GemtesaVibegron12$5,687
Solifenacin Succinate160$4,957
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst205$3,990
CefuroximeCefuroxime Axetil145$2,341
Tolterodine Tartrate ErTolterodine Tartrate24$1,578
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip20$1,514
Fesoterodine Fumarate ErFesoterodine Fumarate11$1,440
Oxybutynin Chloride ErOxybutynin Chloride48$1,306
Levofloxacin41$1,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$765$342,689519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecology providers in Wisconsinon file to place this against a meaningful peer group, so we don't.

Other gynecology in Racine

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →